Watchlist
GHRS · GH Research PLC
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-08-07 at medium conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-13 and is not part of the scored record.
Current thesis
Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next takeout. Phase 3 FDA alignment is the gate.
Kill line
A weekly close below $26 gives back the 2026-07-16 Lilly-deal gap and the July breakout shelf, ending the repricing leg. Secondary: FDA declines Phase 3 alignment or reinstates a hold, or the psychedelic-M&A theme flips saturated with no follow-through deal.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for GHRS —
As of 13 September 2026, the latest FrontierPicks analysis for GH Research PLC (GHRS): Eli Lilly's up-to-$3.8B AtaiBeckley buy (2026-07-16) put a large-cap price on 5-MeO-DMT for depression; GHRS is now the last independent pure-play, with best-in-class inhaled GH001 Phase 2b data, that the sector is repricing as the next takeout. Phase 3 FDA alignment is the gate.
Kill line: A weekly close below $26 gives back the 2026-07-16 Lilly-deal gap and the July breakout shelf, ending the repricing leg. Secondary: FDA declines Phase 3 alignment or reinstates a hold, or the psychedelic-M&A theme flips saturated with no follow-through deal.
Most recent dated event on file: — catalyst 6d ago.
Current Thesis
GH Research's repricing thesis rests on converting GH001 regulatory progress into a pivotal trial start in 2026; a weekly close below $26 or failure to initiate by year-end would break that case. The acquisition comparison remains the 2026-07-16 Lilly–AtaiBeckley agreement reported by Benzinga, but that transaction does not establish acquisition interest in GH Research.
The September refresh adds a dated attention event: GH Research disclosed investor meetings at Morgan Stanley's healthcare conference on 2026-09-14–2026-09-16. The filing contains no pivotal-design agreement or trial-start announcement. September 11 Form 6-K
The narrative is maturing — the 2026-09-11 reference close of $27.20 remains 11.2% below the supplied $30.64 annual high, while the company's news index still lists 2026-08-06 as its latest results release. This is an inference about the story's development, not a measurement of investor flows. Company news index
Bullish and bearish views on GH Research PLC
The model's bull view on GH Research PLC (GHRS), in brief: Regulatory preparation has advanced. The 2026-08-06 update reported July feedback from the US Food and Drug Administration (FDA) supporting Phase 3 readiness of chemistry, manufacturing and controls (CMC) and device plans. Pivotal-design discussions remained open. Company update… The bear view: The decisive agreement remains outstanding. Both cases follow in full.
Bull Case
- Regulatory preparation has advanced. The 2026-08-06 update reported July feedback from the US Food and Drug Administration (FDA) supporting Phase 3 readiness of chemistry, manufacturing and controls (CMC) and device plans. Pivotal-design discussions remained open. Company update
- Financing preceded pivotal execution. Cash, equivalents and marketable securities totaled $362.7 million on 2026-06-30, following $117.5 million of gross offering proceeds during the quarter. These are measured resources; they do not establish the cost of completing development. Second-quarter results
- Scientific exposure has scheduled venues. The 2026-08-06 update disclosed accepted September and October conference posters and an October industry symposium. These provide opportunities to discuss existing evidence; the release did not promise pivotal results at either meeting. Company update
Bear Case
- The decisive agreement remains outstanding. On 2026-08-06, the company still described engagement with the FDA over pivotal design while targeting initiation during 2026. Device readiness alone does not settle the trial protocol. Company update
- Development spending has increased. Research and development expense reached $12.4 million in the quarter ended 2026-06-30 versus $9.0 million a year earlier. The company attributed the increase primarily to clinical development and employee expenses. Second-quarter results
- Bullish coverage is already established. The dated 2026-08-30 Stock Analysis snapshot recorded nine analysts, no Hold or Sell ratings, and analyst targets of $38–$65. That documents agreement among analysts at that date; it does not measure institutional exposure or retail demand.
Setup & Price Structure
The supplied adjusted market series records a $27.20 close on 2026-09-11, a three-month price increase of 28.8%, and a 14-day relative strength index (RSI) of 40.2. The same snapshot places the shares 11.2% below their $30.64 annual high. Those observations show a retained medium-term gain alongside weaker recent momentum; they do not establish that a base has formed.
The $26 July breakout shelf identified in the 2026-08-30 published analysis remains the research invalidation level. A weekly close above the $30.64 reference high, together with announced pivotal initiation during 2026, defines successful confirmation before invalidation. The low-conviction forecast reflects unresolved trial timing and the September 11 price structure; it is an inference, not a measured probability.
The September 11 snapshot supplies neither moving-average values nor direct positioning data. Analyst agreement alone cannot support a crowding conclusion.
Catalyst Calendar (next 30 days)
- 2026-09-28–2026-09-30: International Society for Bipolar Disorders annual conference, using the organizer's registration calendar. GH Research disclosed accepted posters on 2026-08-06; the exact presentation date was not identified. Organizer calendar, company update
- 2026-10-10–2026-10-13: European College of Neuropsychopharmacology congress in Munich. The organizer specifies these dates; GH Research's 2026-08-06 update disclosed posters and an industry symposium. Organizer brochure, company update
Beyond this window, 2026-12-31 is the assessment deadline for the company's stated 2026 pivotal-initiation goal, not a scheduled announcement. No company-confirmed pivotal-start date supports a September 29 initiation assumption.
Elapsed catalysts
- 2026-09-14–2026-09-16: Morgan Stanley Global Healthcare Conference investor meetings in New York, disclosed on 2026-09-11. This is a confirmed communication event, with no clinical readout specified. Form 6-K (passed 4d ago)
What Would Change Our Mind
Loss of the July breakout structure would end the repricing case: a weekly close below $26 is the gradeable condition. Separately, company disclosure of a renewed clinical hold, an initiation delay beyond 2026, or no announced start by 2026-12-31 would invalidate the regulatory-execution thesis.
An FDA-aligned protocol and announced initiation, accompanied by a weekly close above the September 11 reference high of $30.64 before either invalidation condition occurs, would establish the published success condition. Conference attendance by itself cannot satisfy it.
Correlation Notes
The 2026-07-16 Lilly–AtaiBeckley announcement supplies an acquisition comparison for the mechanism, not a measured correlation between GHRS and other psychedelic developers. No paired return sample is available in the September 11 evidence, so no correlation or sector-participation claim is supported. GH Research remains a single-name regulatory setup in this assessment; its own pivotal announcement and the $26 weekly-close condition determine the outcome.
Notes
- Clinical-stage with no product revenue: the equity resolves on GH001 pivotal outcomes and FDA decisions, not on quarterly financials.
- Pivotal initiation is guided only to "2026" with no company-confirmed date; the calendar can stay empty of hard catalysts for months.
- Irish plc with Nasdaq-listed ordinary shares; thin float and concentrated insider ownership produce outsized gaps in both directions on headlines.
- Foreign private issuer reporting on Form 6-K and 20-F, so US domestic-style quarterly and insider filings are not part of the disclosure record.
- Takeout speculation rests on Lilly agreeing to buy the direct competitor on 2026-07-16; the company has disclosed no strategic process of its own.
- Nine covering analysts with no Hold or Sell rating as of 2026-08-30; published targets run $38 to $65.
Related · shared themes
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
RVMD
Revolution Medicines, Inc.
Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to $235 (Guggenheim, 2026-07-09). The three-week digestion off the $192.62 high resolved higher on 2026-07-17 (+3.9% to $186.16) — the breakout retest the prior note wanted.
ABCL
AbCellera Biologics Inc.
AbCellera's monthly hot-flash antibody thesis requires the 2026-10-01 presentation to preserve the Phase 2 efficacy case and a subsequent weekly close above $12.73; a weekly close below $9.75 invalidates it.
See also · stocks to watch